Marginal Zone B-cell Lymphoma – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23006IDB-L5

Select Item

Empower your strategies with our Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions.

Marginal zone B-cell lymphoma is a slow-growing, non-Hodgkin lymphoma that originates from B cells at the margins of lymphoid tissues. It’s divided into three subtypes: extranodal, nodal, and splenic, each with distinct features. Extranodal marginal zone lymphoma primarily affects organs outside the lymph nodes, such as the stomach (gastric MALT lymphoma) or the eye (ocular MALT lymphoma). Symptoms may include painless swelling, fatigue, or gastrointestinal issues. Treatment options depend on the subtype, stage, and individual patient factors and can range from watchful waiting to radiation therapy, chemotherapy, or immunotherapy. Prognosis is generally favorable, with a good response to treatment and long-term survival for many patients.

The Marginal Zone B-cell Lymphoma drugs in development market research report provide comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marginal Zone B-cell Lymphoma and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Marginal Zone B-cell Lymphoma
Key Targets
· B Lymphocyte Antigen CD19; B Lymphocyte Antigen CD20; Tyrosine Protein Kinase BTK; CD3 ; Apoptosis Regulator Bcl 2; B Cell Receptor CD22; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform; Leukocyte Surface Antigen CD47; Programmed Cell Death Protein 1; and T Cell Surface Glycoprotein CD3 Epsilon Chain
Key Mechanisms of Action
· Tyrosine Protein Kinase BTK Inhibitor; B Lymphocyte Antigen CD20 Inhibitor; Apoptosis Regulator Bcl 2 Inhibitor; CD3 Agonist; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor; B Lymphocyte Antigen CD19 Inhibitor; Leukocyte Surface Antigen CD47 Inhibitor; Programmed Cell Death Protein 1 Antagonist; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform Inhibitor; and T Cell Surface Glycoprotein CD3 Epsilon Chain Agonist
Key Routes of Administration
· Intravenous; Oral; Parenteral; Subcutaneous; Intravenous Drip; Intratumor; Intralesional; Intraperitoneal; Inhalational; and Topical
Key Molecule Types
· Small Molecule; Gene-Modified Cell Therapy; Monoclonal Antibody; Monoclonal Antibody Conjugated; Cell Therapy; Fusion Protein; Biologic; Antisense RNAi Oligonucleotide; Polysaccharide; and Recombinant Protein
Major Companies
· BeiGene Ltd; Bristol-Myers Squibb Co; F. Hoffmann-La Roche Ltd; Merck & Co Inc; AbbVie Inc; Novartis AG; InnoCare Pharma Ltd; Hutchison MediPharma Ltd; Incyte Corp; and General Hospital of the People's Liberation Army

Scope

  • Therapeutics in Development: Covering 197 molecules, with 178 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Marginal Zone B-cell Lymphoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Marginal Zone B-cell Lymphoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Marginal Zone B-cell Lymphoma treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
Abclon Inc
Accutar Biotechnology Inc
Achelois BioPharma Inc
Adicet Bio Inc
Advenchen Laboratories LLC
Allarity Therapeutics Inc
Allogene Therapeutics Inc
ALX Oncology Holdings Inc
Amgen Inc
Antengene Corp Ltd
AstraZeneca Plc
Aurigene Oncology Ltd
Autolus Therapeutics Plc
BeiGene Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Path Holdings Inc
BioIntegrator
BioInvent International AB
BioNova Pharmaceuticals Ltd
Boryung Pharmaceutical Co Ltd
Boston Immune Technologies and Therapeutics Inc
Bristol-Myers Squibb Co
Byondis BV
California Institute for Biomedical Research
CARGO Therapeutics Inc
Caribou Biosciences Inc
Carna Biosciences Inc
CASI Pharmaceuticals Inc
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Century Therapeutics Inc
Chengdu Hyperway Pharmaceutical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CHO Pharma Inc
CoImmune Inc
CSPC Pharmaceutical Group Ltd
Cullinan Oncology Inc
Curis Inc
Curon Biopharmaceutical Ltd
Daiichi Sankyo Co Ltd
Debiopharm International SA
Dizal Pharmaceutical Co Ltd
Duet Therapeutics Inc
Eli Lilly and Co
Enterome Bioscience SA
Evopoint Bioscience Co Ltd
F. Hoffmann-La Roche Ltd
Fosun Pharma Kite Biotechnology Co Ltd
Galapagos NV
Gamida Cell Ltd
GC Cell Corp
Genentech USA Inc
General Hospital of the People's Liberation Army
Genmab AS
Gilead Sciences Inc
Gracell Biotechnologies Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangdong Second Provincial General Hospital
Guangzhou BeBetter Medicine Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hibercell Inc
Hualan Biological Engineering Inc
Huazhong University of Science & Technology
Hutchison MediPharma Ltd
I-Mab
IGM Biosciences Inc
ImmuneOncia Therapeutics Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunoAct Pvt Ltd
Incyte Corp
Innate Pharma SA
InnoCare Pharma Ltd
Innovent Biologics Inc
Institute of Biomedical Research of Salamanca
Ipsen SA
ITabMed Co Ltd
Janssen Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JW Cayman Therapeutics Co Ltd
Karyopharm Therapeutics Inc
KeyMed Biosciences Inc
Lanzhou Institute of Biological Products Co Ltd
Les Laboratoires Servier SAS
Light Chain Bioscience
Loxo Oncology Inc
Marino Biotechnology Co Ltd
Massachusetts General Hospital
Mayo Clinic
Medical College of Wisconsin
MEI Pharma Inc
Merck & Co Inc
Miltenyi Biomedicine GmbH
MiNK Therapeutics Inc
MorphoSys AG
Mustang Bio Inc
Nagoya University Hospital
Nanjing Sanhome Pharmaceutical Co Ltd
National Taiwan University Hospital
Newave Pharmaceutical Inc
Nkarta Inc
Novartis AG
Nurix Therapeutics Inc
Oncternal Therapeutics
PeproMene Bio Inc
Prelude Therapeutics Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Salarius Pharmaceuticals Inc
Sana Biotechnology Inc
Sanofi
Secura Bio Inc
SELLAS Life Sciences Group Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
Shanghai Longyao Biotechnology Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
SIRPant Immunotherapeutics Inc
Sorrento Therapeutics Inc
Spexis AG
Stemline Therapeutics Inc
Step Pharma
Sunnycell Therapeutics Ltd
Suzhou Fundamenta Therapeutics Co Ltd
Swedish Orphan Biovitrum AB
SymBio Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
TG Therapeutics Inc
TransThera Sciences (Nanjing) Inc
Triphase Accelerator Corp
UNC Lineberger Comprehensive Cancer Center
University of Colorado Denver
University of Texas MD Anderson Cancer Center
UTC Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xuzhou Medical College
Xuzhou Medical University
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd
Zai Lab Ltd
Zentalis Pharmaceuticals Inc
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang DTRM Biopharma LLC
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Longchuan Biomedical Technology Co Ltd
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhejiang University
Zhejiang University School of Medicine Hospital 1
Zibo Baiji Changsheng Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Marginal Zone B-cell Lymphoma reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 in real time.

  • Access a live Marginal Zone B-cell Lymphoma – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more